Brokerage Firm Rating Update on Horizon Pharma plc (HZNP)

Horizon Pharma plc (HZNP) : 6 brokerage houses believe that Horizon Pharma plc (HZNP) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Horizon Pharma plc (HZNP). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 7 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.29.

Horizon Pharma plc (HZNP) stock is expected to deviate a maximum of $8.46 from the average target price of $32.29 for the short term period. 7 Street Experts have initiated coverage on the stock with the most promising target being $45 and the most muted being $24.


For the current week, the company shares have a recommendation consensus of Buy. Also, In a research note released to the investors, Citigroup maintains its rating on Horizon Pharma plc (NASDAQ:HZNP).The analysts at the brokerage house have a current rating of Neutral on the shares. In a recent information released to the investors, Citigroup raises the new price target from $18 per share to $21 per share. The rating by the firm was issued on August 9, 2016.

Horizon Pharma plc (NASDAQ:HZNP): stock was range-bound between the intraday low of $17.64 and the intraday high of $18.29 after having opened at $17.96 on Wednesdays session. The stock finally closed in the red at $17.96, a loss of -0.39%. The stock remained in the red for the whole trading day. The total traded volume was 3,449,380 shares. The stock failed to cross $18.29 in Wednesdays trading. The stocks closing price on Thursday was $17.9.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.